Welcome to our dedicated page for Oragenics news (Ticker: OGEN), a resource for investors and traders seeking the latest updates and insights on Oragenics stock.
Oragenics Inc (OGEN) is a clinical-stage biopharmaceutical company pioneering intranasal therapies for neurological conditions and infectious diseases. This news hub provides investors and researchers with timely updates on the company's innovative pipeline, including nasal delivery systems and oral health advancements.
Access authoritative updates on clinical trial progress, regulatory milestones, and scientific breakthroughs. Our curated collection features official press releases covering neurosteroid development, probiotic oral care innovations, and FDA-accepted research methodologies.
Key updates include developments in concussion treatment candidates, nasal casting study results, and strategic partnerships. All content is verified through primary sources to ensure accuracy in reporting scientific advancements and corporate developments.
Bookmark this page for streamlined access to Oragenics' latest achievements in drug delivery technology and therapeutic research. Check regularly for essential updates impacting neurology and infectious disease treatment landscapes.
Oragenics, Inc. (AMEX: OGEN) announced the adjournment of its reconvened annual meeting of shareholders on August 23, 2021, due to a lack of quorum. A new date for the annual meeting will be established, along with a new record date, as the previous one from May 5, 2021 is no longer valid. Oragenics focuses on combating infectious diseases, with its lead product, Terra CoV-2, aimed at preventing COVID-19 and its variants.
Oragenics, Inc. (NYSE American: OGEN) has entered a licensing agreement with the National Research Council of Canada to develop next-generation vaccines against SARS-CoV-2 and its variants. The collaboration leverages NRC technologies, enhancing the speed of cell line production for spike protein antigens from six months to six to eight weeks. The company has initiated preclinical studies and aims to advance vaccine candidates rapidly. This strategy may position Oragenics competitively against existing vaccines, particularly with additional options like intranasal administration.
Oragenics, Inc. (NYSE American: OGEN) has announced that its annual shareholder meeting, convened on June 30, 2021, was adjourned due to a lack of quorum. The meeting is rescheduled for August 23, 2021, at 4:00 p.m. The Company continues to solicit votes to meet the quorum requirement of a majority of shares. Currently, only 40% of the shares are represented by proxy. Shareholders of record as of May 5, 2021, are urged to vote by August 22, 2021. If quorum is not reached, further adjournment may incur additional costs.
Oragenics (NYSE American: OGEN) affirms its commitment to advancing its business strategy following the resignation of CEO Alan Joslyn. Executive Chairman Frederick W. Telling will take a more active management role. The company is focused on developing the Terra CoV-2 vaccine to combat COVID-19 and antibiotic resistance through its lantibiotics program. Oragenics has a strong leadership team and has recently raised nearly $22 million to support its initiatives, which positions it to continue operations well into 2022.
Oragenics, Inc. (NYSE American: OGEN) announced the resignation of Dr. Alan Joslyn as CEO and President, effective May 2, 2021. Dr. Frederick Telling transitions to Executive Chairman, while CFO Mr. Sullivan takes on the role of interim principal executive officer. The Board will guide the company in the interim as they seek a new CEO to lead the Terra CoV-2 vaccine development. Oragenics focuses on creating a vaccine to combat COVID-19 and developing new antibiotics. The company expresses gratitude for Dr. Joslyn's contributions and remains committed to future growth.
Oragenics, Inc. (NYSE American: OGEN) has entered into a material transfer agreement with Biodextris Inc. regarding the use of three intranasal mucosal adjuvants for its Terra CoV-2 vaccine against COVID-19. The adjuvants—BDX100, BDX300, and BDX301—aim to enhance immune response and manufacturing efficiency. This collaboration will facilitate preclinical studies essential for FDA Investigational New Drug applications and potential clinical trials. Oragenics' vaccine offers advantages like refrigerated storage, aiming to address ongoing COVID-19 vaccination needs.
Oragenics, Inc. (NYSE American: OGEN) announced that its CEO, Alan Joslyn, Ph.D., will participate in two virtual investment conferences in March 2021. The events are the H.C. Wainwright Global Life Sciences Virtual Conference on March 9-10 and the Roth Conference on March 15-17. A prerecorded presentation for the Roth Conference will be available on the Company's website starting March 9. Oragenics focuses on developing a vaccine for COVID-19 and novel antibiotics, leveraging research from the National Institutes of Health.
Oragenics, Inc. (NYSE American: OGEN) announced a successful capital raise of approximately $20 million through a sales agreement with A.G.P./Alliance Global Partners. The firm also gained around $1.9 million from exercising common stock warrants. Furthermore, Oragenics will redeem all shares of its Series C Preferred Stock, valued at $5.6 million, which eliminates a 20% preferred dividend. These funds will support the Phase 2 clinical trial of its SARS CoV-2 vaccine, Terra CoV-2, and advance its lantibiotics program.
Oragenics, Inc. (NYSE American: OGEN) has announced positive results for its COVID-19 vaccine candidate, Terra CoV-2. Research from the NIH indicates that the spike protein S-2P, licensed by Oragenics, induced protective immunity in mice infected with SARS-CoV-2. The study showed complete inhibition of virus growth in treated mice, with significant immune responses measured. The results support the ongoing development of Terra CoV-2, a candidate positioned to address the estimated 12-14 billion doses needed globally for COVID-19 vaccination. The company aims to file an Investigational New Drug application soon.
Oragenics, Inc. (NYSE American: OGEN) issued a letter to stockholders from CEO Alan Joslyn, updating on the COVID-19 vaccine Terra CoV-2. The firm has gained confidence from recent vaccine developments and has a nonexclusive license from the NIH for a prefusion stabilized spike protein vaccine candidate. Oragenics held a pre-IND meeting with the FDA, streamlining its timelines. The company raised $12.5 million in recent financing, aiming to advance vaccine studies. Despite financial hurdles, Oragenics believes in market demand for multiple vaccines against COVID-19.
